Thrombolytic therapy in Europe: current status

Thrombolytic therapy in Europe: current status.

Thrombolytic therapy is a practical, effective approach to the management of acute myocardial infarction that is widely used in Europe today. Early European trials demonstrated a clear reduction in mortality in patients who received thrombolytic therapy compared with those given conventional treatment. The findings of experimental studies suggest that early reperfusion of the infarct-related ar...

Current status of thrombolytic agents in acute cerebrovascular disease.

Thrombolytic therapy.

Thrombolytic therapy, which involves the administration of agents designed to increase fibrinolytic capacity, has been utilized in respiratory medicine for more than 50 years. A variety of agents have been used to effect thrombolysis, including urokinase plasminogen activator (uPA) and streptokinase. Tissue plasminogen activator (tPA) has also been used to effect thrombolysis. Both uPA and tPA ...

Thrombolytic Therapy.

The purpose of this communication is to review briefly the agents available at the present time for use in thrombolytic therapy and to indicate why we believe that at the present time streptokinase is the only suitable agent for extended clinical trial. An account will then be given of the use of streptokinase administered by local perfusion in the treatment of peripheral arterial occlusion and...

Current Status of Estrogen Therapy

Replacement of deficient hormones is an important axis of anti-aging medicine since aging is caused and manifested by various hormonal declines. Somatopause has been treated with growth hormone; andropause with testosterone; thyropause with thyroid hormones; and menopause with estrogen or other natural substances (including isoflavone and black cohosh), whereas facial flush, genital atrophy and...